41 results about "Liver Insufficiency" patented technology

Methods and uses of increasing or accelerating liver regeneration in a subject in need thereof are provided. In some aspects, such methods and uses comprise administering an effective amount of an androgen receptor inhibitor to a subject in need thereof, including, but not limited to, a subject suffering from one or more risk factors of post-hepatectomy liver failure. Any androgen receptor is contemplated for use in the methods described herein including, but not limited to, enzalutamide, apalutamide, bicalutamide, darolutamide, flutamide, nilutamide, or proxalutamide.

The invention belongs to the technical field of biomedical engineering, and discloses a multiple biomarker detection system for diagnosis and classification of hepatic failure acute kidney injury, comprising a biomarker library construction module for obtaining historical hepatic failure acute kidney injury data to construct a biomarker library; the historical hepatic failure acute kidney injury data comprises biomarker data, pathological image data and patient clinical data; the data processing module is used for preprocessing the acquired biomarker data, pathological image data and patient clinical data to obtain a biomarker feature data set, a pathological image feature data set and a clinical feature data set; the acute kidney injury diagnosis module is used for fusing the biomarker feature data set, the pathological image feature data set and the clinical feature data set to obtain a comprehensive feature data set; inputting the comprehensive feature data set into a trained acute kidney injury diagnosis model, and predicting to obtain acute kidney injury type data; and the diagnosis accuracy is improved.

This invention discloses a polyethylene glycol-modified magnesium boride nanosheet and its application in treating acute liver failure and hepatic encephalopathy caused by acetaminophen. The nanosheet uses magnesium boride nanosheets as a core, with polyethylene glycol modified on the surface to improve biocompatibility. The nanosheet of this invention exhibits good antioxidant properties and can be used to prepare nanomedicines for treating acute liver failure and / or hepatic encephalopathy caused by acetaminophen. It generates reducing hydrogen gas through a hydrolysis reaction, effectively scavenging reactive oxygen species at the site of liver failure, thereby inhibiting inflammatory responses and effectively alleviating symptoms caused by acute liver failure.

The invention relates to application of serum mucoid or Tax1 binding protein 1 in preparation of a medicine for treating medicine-induced liver injury or organ ischemia-reperfusion injury. Experiments prove that by using an adeno-associated virus (AAV) carrying an Orm2 gene, ORM2 recombinant protein or knocking down a TAX1BP1 gene, liver injury and liver failure, ischemia reperfusion injury of the liver, ischemia reperfusion injury of the kidney and ischemia reperfusion induction of intestines induced by APAP treatment can be effectively relieved, and the application has the advantages that the liver injury and liver failure, the ischemia reperfusion injury of the kidney and the ischemia reperfusion induction of the intestine can be effectively relieved; and a new target spot and a new treatment method are provided for treating the ferroptosis-related organ injury.

A lipid-containing composition, by weight, includes phospholipids, and one or more of vegetable oil, medium-chain triglycerides, antioxidants, and sodium oleate. It has been verified that the various compositions provided by this invention competitively capture protein-bound toxoids in the blood, thereby achieving the purpose of clearing protein-bound toxoids from the blood, especially for patients with liver failure, and also alleviating oxidative stress in patients during dialysis treatment.

The application belongs to the technical field of biological detection, and particularly relates to the use of apolipoprotein A-I in the preparation of a diagnostic reagent or system for predicting the risk of severe acute hepatitis E. The application first discloses and verifies the significant correlation between the serum apolipoprotein A-I (apoA-I) level and the adverse clinical outcomes (including severe jaundice, liver failure and death) of patients with acute hepatitis E, and establishes the risk interpretation threshold (0.675 g / L and 0.435 g / L) with clinical practical value. The application can objectively and early identify high-risk patients, and provides a powerful auxiliary tool for clinical stratified management and resource optimization.

Subject matter of the present invention is an angiotensin-receptor-agonist and / or a precursor thereof for use in the treatment of a disease in a subject, • wherein said disease is selected from the group comprising heart failure, chronic heart failure, acute heart failure (AHF), myocardial infarction (MI), stroke, liver failure, burn injuries, traumatic injuries, severe infection (microbial, viral (e.g. AIDS), parasitic diseases (e.g. Malaria)), SIRS or sepsis, cancer, acute kidney injury (AKI), CNS disorders (e.g. seizures, neurodegenerative diseases), autoimmune diseases, vascular diseases, hypotension and shock, and • wherein said subject has an amount of DPP3 protein and / or DPP3 activity in a sample of bodily fluid that is above a predetermined threshold.

The invention discloses a preparation method and application of a hepatic parenchymal cell targeting gene delivery system, and relates to construction and preparation of a hepatic parenchymal cell targeting lipid material GalNAc-PEG2000-DSPE modified MKK4-siRNA (siMKK4) loaded lipid nanoparticle gene delivery system GalNAc-LNP-siMKK4, and the hepatic parenchymal cell targeting gene delivery system can be used for active targeting gene therapy of hepatic failure. The parenchymal hepatic cell targeted gene delivery system selects siMKK4 as a liver regeneration promoting gene therapy drug, has the advantages of clear target spot and capability of accurately silencing a target gene, and can protect siMKK4 from being degraded by extracellular nuclease as a gene delivery carrier, so that the targeted gene delivery system has a good application prospect. N-acetylgalactosamine (GalNAc) is selected as a target head, so that therapeutic genes can be precisely targeted and delivered to parenchymal hepatic cells, the risk of tumorigenesis of other parts of an organism can be reduced while liver regeneration is promoted, and a new thought and a new method are provided for liver regeneration treatment of hepatic failure patients.

The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, able to inhibit Yellow Fever Virus (YFV) viral genome expression. Also disclosed are pharmaceutical compositions that include YFV RNAi agents and methods of use thereof. The YFV RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that comprise N-acetyl-galactosamine, to facilitate the delivery to hepatocyte cells. Delivery of the YFV RNAi agents in vivo provides for inhibition of YFV viral genome expression. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms caused by YFV infection, such as liver failure.

The present invention relates to compounds for use in the treatment of liver failure.

The invention provides a capecitabine prodrug for reducing liver metabolism burden and application thereof, a derivative formed by introducing a masking group R capable of enzymolysis or chemical hydrolysis into 5 '-hydroxyl or N-amino of a capecitabine molecule, and the R is selected from amino-acid ester, phosphate, polyethylene glycol chain or cholic acid conjugation group. The prodrug can be selectively activated in intestinal tracts or tumor tissues through a non-UGT1A1 dependent pathway, and 5-fluorouracil is finally released through metabolism. Due to the characteristic, the competitive inhibition of the prototype capecitabine on liver UGT1A1 enzyme is obviously reduced, and the interference on bilirubin binding and excretion pathways is fundamentally reduced. The pharmaceutical composition disclosed by the invention is suitable for patients with UGT1A1 gene defects or liver insufficiency. While good anti-tumor activity is maintained, the hepatotoxicity is remarkably reduced, the medication safety is improved, and good clinical application prospects are achieved.

A system for managing liver disease, the system comprising an electronic medical record system comprising a plurality of patient records. The system comprising a patient management platform configured to access the electronic medical record (EMR) system to retrieve medical records of one or more patients, analyze the medical records to selectively identify data related to a liver condition, interface with one or more data analysis platforms configured to receive and analyze the data related to a liver condition. Based on analysis by the patient management interface and / or the data analysis platforms, a display is generated comprising: specific liver-related patient attributes and conditions, and at least one of: a liver health prognosis or a recommended treatment for addressing the liver condition corresponding to the one or more patients. The liver condition can comprise one or more of: cancer, cirrhosis, liver failure, fatty liver disease, steatosis, ischemia, and / or hepatitis.

Methods are disclosed for treating end-stage liver failure in a subject that include administering to the subject a therapeutically effective amount of a recombinant mRNA encoding HNF4α isoform 2. The methods can include administering a lipid nanoparticle including the recombinant mRNA to the subject. Also disclosed are recombinant mRNA encoding an HNF4α isoform 1 or HNF4α isoform 2, and lipid nanoparticles include the recombinant mRNA. Methods are also for treating liver disease or end-stage liver failure in a subject that include administering to the subject a therapeutically effective amount of a recombinant mRNA encoding HNF4α isoform 1.

The present application relates to a kind of protein combination, kit and system for predicting secondary infection of hepatitis B related liver failure patient, including the use of protein combination in the preparation for predicting secondary infection of hepatitis B related liver failure patient, the combination includes lysozyme LYZ, calmodulin 1 CALM1, heparin cofactor II SERPIND1 and cutin DPT.It is directly reflected that the combination is biomarker "inflammation-coagulation imbalance" this core mechanism of liver disease secondary infection, with high specificity, and the combination is not interfered by liver disease background, more can truly reflect the potential reaction state of body to infection under liver disease background, to overcome the problem of "failure" and "false negative" of traditional index ";The combination can significantly change concentration when patient is admitted to hospital early, without clinical infection signs, to provide key time window for early preventive treatment.

The invention provides an application of SETDB1 as a drug target for preventing and / or treating acute liver injury and hepatic failure. The acute liver injury and hepatic failure are relieved by knocking out an SETDB1 gene or inhibiting SETDB1 enzyme activity. Experiments prove that the SETDB1 gene is specifically knocked out of the liver or a small-molecule inhibitor SETDB1-TTD-IN-1 is used, acute liver injury and hepatic failure induced by acetaminophen can be remarkably relieved, and the acute liver injury and hepatic failure are shown as reduction of hepatic cell necrosis and remarkable improvement of liver function indexes. The discovery provides new targets and candidate compounds for developing specific drugs for treating acute liver injury and hepatic failure, and has important clinical transformation value.

This invention discloses the application of β-hydroxybutyric acid (BHB) in the preparation of products that promote hepatocyte proliferation and liver regeneration. This invention discovers that β-hydroxybutyric acid can promote liver regeneration and recovery by promoting the proliferation of hepatocytes in the residual liver after partial hepatectomy. Therefore, β-hydroxybutyric acid can be used to prepare products that promote liver regeneration. This invention not only discloses the application of β-hydroxybutyric acid in promoting liver regeneration, providing a drug source for the development of products that promote liver regeneration, but also provides a theoretical basis for subsequent clinical intervention strategies to promote liver regeneration. This helps to improve liver regeneration capacity and avoid poor prognosis and liver failure caused by insufficient liver regeneration capacity after partial hepatectomy or living donor liver transplantation.

The lipid-containing composition comprises phospholipid, and one or more of vegetable oil, medium-chain triglyceride, an antioxidant and sodium oleate according to a weight ratio. Through verification, various compositions provided by the invention have the effect of competitively capturing the protein-binding toxoid in the blood, so that the purpose of removing the protein-binding toxoid in the blood is achieved, and particularly, the effect of removing the protein-binding toxoid in the blood of a liver failure patient is more obvious; the oxidative stress state of a patient in the dialysis treatment process is also relieved.

This invention discloses the application of β-1,4-galactosyltransferase 1 and its inhibitors in liver diseases, particularly acute liver injury and liver failure. The application of β-1,4-galactosyltransferase 1 and its inhibitors in acute liver injury and liver failure provides the correlation between β-1,4-galactosyltransferase 1 and acute liver injury and liver failure, confirming that inhibiting the activity of β-1,4-galactosyltransferase 1 can alleviate acute liver injury and liver failure. β-1,4-galactosyltransferase 1 can serve as a drug target for screening acute and chronic hepatitis, liver injury, fatty liver, liver fibrosis, and acute and chronic liver failure. This invention also confirms the alleviating effect of β-1,4-galactosyltransferase 1 inhibitors on acute liver failure. β-1,4-galactosyltransferase 1 inhibitors improve acute liver failure by reducing the enzyme activity or protein expression of β-1,4-galactosyltransferase 1.

This invention discloses a kit, its application, and its method for evaluating the prognostic outcome of liver failure. The invention analyzes the correlation between high-throughput transcriptome sequencing and disease outcome (death, survival), and verifies the results using qPCR. The results show that VSIG4 is specifically highly expressed in patients with poor liver failure outcomes (death) and has a strong, stable, and reliable correlation with the outcome (death, survival). The kit's detection process is simple, reproducible, and can be performed by qualified technicians, making it highly feasible. It provides accurate early warning and prediction results for liver failure outcomes, promptly reflecting the disease status of liver failure patients. This allows for early warning and prediction of liver failure outcomes, guiding physicians in developing targeted treatment plans, enabling early treatment, and reducing short-term mortality.

A lipid-containing composition, by weight, includes phospholipids, and one or more of vegetable oil, medium-chain triglycerides, antioxidants, and sodium oleate. It has been verified that the various compositions provided by this invention competitively capture protein-bound toxoids in the blood, thereby achieving the purpose of clearing protein-bound toxoids from the blood, especially for patients with liver failure, and also alleviating oxidative stress in patients during dialysis treatment.

The invention belongs to the technical field of medicines, and particularly relates to a Beijing pharmaceutical composition for preparing a medicine for repairing liver injury, which is extracted from the following raw materials in parts by weight: 17-20 parts of oriental wormwood, 8-12 parts of polyporus umbellatus, 3-4 parts of rhizoma atractylodis, 8-12 parts of akebiaquinata, 10-14 parts of radix bupleuri, 10-14 parts of poria cocos, 10-14 parts of semen plantaginis, 10-14 parts of cape jasmine and 4-6 parts of rhizoma alismatis. The composition disclosed by the invention can effectively relieve jaundice caused by damp-heat, relieve skin and hair yellow staining and digestive tract symptoms, promote abnormal excrement recovery, improve the inflammatory state of a body, protect liver tissues, reduce necrosis, degeneration and inflammatory infiltration of liver cells, relieve hepatic congestion, regulate liver function indexes and remarkably reduce ALT and AST levels of serum. The traditional Chinese medicine composition has the effects of eliminating dampness and heat and soothing the liver to relieve pain, and can be used for people with hepatic insufficiency, abdominal pain, jaundice, bitter and sticky mouth, whole body sleepiness, chest and hypochondrium swelling and stuffiness, red tongue, yellow / yellow and greasy tongue coating and the like.

The invention relates to compounds for use in the treatment of liver failure.

The invention discloses an injectable decellularized matrix-liver organ three-dimensional compound as well as a preparation method and application thereof. The three-dimensional compound comprises decellularized matrix fibers and liver organs which form a pasty compound, the length of the decellularized matrix fiber is 0.2-2mm, and the decellularized matrix fiber is obtained by selecting mammalian dermis, performing epidermis removal and degreasing, performing soaking treatment with alkali and a nonionic surfactant in sequence, then performing decellularization, and performing freeze-drying and ball milling. The liver organ is obtained by placing bile in matrigel for culture, amplification and induction. According to the invention, a Mini-liver complex with injectability, self-adhesion, biological activity and metabolic function is formed, unified integration of a material scaffold, signal delivery and cell function is realized, and an innovative solution with remarkable clinical potential is provided for local repair after hepatic resection and hepatic failure.

The present disclosure relates to a new water-soluble fullerene derivative and a preparation method thereof, and application of the water-soluble fullerene material in preventing and treating liver damage / liver failure. The fullerene material of the present disclosure can efficiently scavenge active free radicals, reduce liver oxidative stress, restore normal liver function indicators, reduce liver necrosis, and prevent and treat drug-induced liver damage / liver failure.

The invention discloses a novel ALPPS mouse model as well as a construction method and application thereof. The construction method of the novel ALPPS mouse model comprises the following steps: anesthetizing and opening the abdomen of a tested mouse to expose the upper abdomen; sequentially ligating a portal vein supplying CL, a portal vein of RL and a common trunk portal vein of LML and LLL; ligation of the liver pedicel of LLL is carried out, and LLL is completely cut off; the liver parenchyma between the RML and the LML is separated; suturing and closing the abdomen layer by layer after fully stopping bleeding. According to the novel ALPPS mouse model, the right middle leaf of the liver is reserved, and the right middle leaf of the liver accounts for 20% of the whole liver, so that the occurrence rate of postoperative hepatic failure and mouse death can be reduced. According to the model, only three common portal vein branches of the caudate lobe, the right lobe, the left lateral lobe and the left middle lobe need to be ligated in sequence, and operation steps are simplified. The novel ALPPS mouse model constructed by using the method is obvious in liver proliferation effect, and the survival rate of postoperative mice is high.

The invention belongs to the technical field of biomarker detection, discloses a biomarker detection method for early diagnosis of gestational liver injury, solves the problems that existing diagnosis of the gestational liver injury depends on laboratory large-scale equipment, consumes long time and is insufficient in accuracy of a single index, can realize rapid early screening of primary medical institutions, and improves the diagnosis accuracy of the gestational liver injury. The risk of serious complications such as gestational hepatic failure is reduced; all the modules are connected through plug-in interfaces, the assembly time is less than or equal to 2 minutes, the weight of the whole device is only 150g, the size of the whole device is equivalent to that of a mobile phone, the device is adaptive to primary screening scenes of primary clinics, community hospitals and homes, and the whole process of sampling, detection and result obtaining is completed within 30 minutes.

The application discloses a cerium nanoscale enzyme composite active material and application thereof in liver failure treatment, and belongs to the technical field of nanomaterials. The application combines miR122 and cerium dioxide nanoscale enzyme functions, develops a new stem cell differentiation inducer, i.e., a cerium nanoscale enzyme composite active material, and deeply studies the potential mechanism of catalytically active nanoscale enzyme material in regulating stem cell fate. After modification, the cerium dioxide nanoscale enzyme can be used for delivering miR122 into stem cells, so that miR122 is highly enriched in cells, thereby inducing liver differentiation. Meanwhile, the catalytic activity of the cerium dioxide nanoscale enzyme can regulate intracellular ROS homeostasis, protect mitochondria from ROS-induced damage, thereby maintaining mitochondrial function and meeting the energy demand in the differentiation process, which is crucial for the successful differentiation of stem cells. In order to solve the problem of impaired viability in hepatocyte transplantation, it is proposed to coat a layer of Ce 4+ -polyphenol skeleton on the surface of induced hepatocyte-like cells (iHLCs), further protecting the function and viability of hepatocytes after transplantation, and improving the in-vivo treatment effect.

The invention belongs to the field of biological medicine, and particularly relates to application of CD177 positive neutrophil in liver regeneration. A series of experiments reveal that neutrophil is an immune cell necessary for liver regeneration after a liver resection operation, especially after a two-step liver resection operation (ALPPS) combining liver separation and portal vein ligation, and after the neutrophil is depleted by an antibody, liver cell proliferation and liver volume increase are remarkably inhibited. The invention further finds that the CD177 positive neutrophil is a specific functional subgroup which plays a key role in the CD177 positive neutrophil. Liver regeneration can be obviously inhibited by clearing the CD177 positive neutrophil in the mouse body, and inhibited liver regeneration can be recovered by in-vivo feedback of the CD177 positive neutrophil. The invention discloses an unknown effect of the CD177 positive neutrophil in promotion of ALPPS induced liver regeneration previously. The research lays a foundation for a strategy taking the neutrophil as a target spot, and a regenerative liver microenvironment is expected to be established and is used for preventing and treating hepatic failure.

The present invention relates to a pharmaceutical composition or a functional food composition for preventing or treating a liver disease selected from the group consisting of fatty hepatitis, liver fibrosis, and liver cirrhosis. The triazole derivative compound according to the present invention can reduce the accumulation of collagen in liver tissue and significantly inhibit the expression of inflammatory factors. Therefore, unlike conventional drugs that have only a simple lipid-lowering effect, the triazole derivative compound effectively prevents the progression of a series of serious liver diseases, from excessive fibrosis of liver tissue to tissue cirrhosis, resulting in a decrease in the number of hepatocytes and liver failure, thereby effectively serving as a composition for fundamentally treating liver fibrosis and liver cirrhosis.